New findings could pave way for treating autoimmune diseases

Scientists from A*STAR's Bioprocessing Technology Institute (BTI) have established a clearer relationship between two cells which serve our body's natural defence mechanisms against diseases and infections. Their findings, published in the prestigious journal CELL REPORTS, will help the medical community better understand autoimmunity and could pave the way for treatment of autoimmune diseases.

Natural killer T (NKT) cells and B cells are two of many immune cell types that work in tandem to help the body fight against foreign infectious agents. NKT cells have very potent functions and are crucial to the immune system despite making up only a small percentage of white blood cells. While scientists have established that NKT cells can promote the production of antibodies by B cells to combat infection, little is known about the effect of B cells on NKT cells until now.

New findings could pave way for treating autoimmune diseases

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

UCLA research may lead to novel treatment for PH1

UCLA research may lead to novel treatment for PH1

FDA Approves Keytruda (pembrolizumab) for Advanced Melanoma

FDA Approves Keytruda (pembrolizumab) for Advanced Melanoma

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. Many turn to conservative management such as diet and lifestyle changes, however if this does not provide relief, women should speak with their healthcare professional about prescription treatment options.

Diclegis (see structure) is the only FDA-approved prescription NVP treatment for women who do not respond to conservative management. Approved in April 2013, the FDA granted Diclegis Pregnancy Category A status, its highest rating.

Duchesnay USA, the maker of Diclegis, is dedicated to providing pregnant women with safe and effective pharmacological treatments.

Now, women experiencing morning sickness can benefit from Diclegis drug

Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline

 Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D). Actavis' NDA for eluxadoline has been granted priority review status by the FDA.

Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline

Small Study Hints Fish Oil Might Ease Tough-to-Treat Epilepsy - Drugs.com MedNews

Small Study Hints Fish Oil Might Ease Tough-to-Treat Epilepsy 

Small Study Hints Fish Oil Might Ease Tough-to-Treat Epilepsy - Drugs.com MedNews

Small Study Hints Fish Oil Might Ease Tough-to-Treat Epilepsy